3SBio Partners with Pfizer for Global Licensing of Oncology Antibody

An update from 3SBio ( (HK:1530) ) is now available.

3SBio, Inc. has entered into an exclusive licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707, granting Pfizer rights to develop, manufacture, and commercialize the product worldwide, excluding mainland China. This agreement includes an upfront payment of $1.25 billion to 3SBio, with potential additional payments up to $4.8 billion, and positions 3SBio strategically in the global oncology market, enhancing its industry standing and providing significant financial benefits.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

More about 3SBio

3SBio, Inc. is a biopharmaceutical company involved in the development, manufacturing, and commercialization of pharmaceutical products. The company focuses on innovative therapies, particularly in the field of oncology, with a strong market presence in China.

YTD Price Performance: 109.54%

Average Trading Volume: 49,271,185

Technical Sentiment Signal: Buy

Current Market Cap: HK$30.56B

Find detailed analytics on 1530 stock on TipRanks’ Stock Analysis page.